HSBC appoints new Head of Wealth and Personal Banking in Sri Lanka | Daily FT

Published by
Daily Financial Times

HSBC Sri Lanka has appointed James Rebert as the Head of Wealth and Personal Banking with immediate effect. James succeeds Nadeesha Senaratne who led the growth and development of the Wealth and Personal Banking franchise in Sri Lanka over the past four years before moving to PT Bank HSBC Indonesia to assume his new role. James counts over 18 years of experience working at HSBC in both Sri Lanka and Hong Kong in the regional office and in the local business. Prior to taking on his new role, James was Head of International Customer On-boarding and Cross Border in Wealth and Personal Banking, HS… Continue reading “HSBC appoints new Head of Wealth and Personal Banking in Sri Lanka | Daily FT”

LifeBank Chain Brings Ultimate Gene and Cell Therapy Benefits to Everyone

LifeBank Chain (LBC) focuses on genetics and cell research, with the purposes of furthering human longevity and expanding access to genetics and cell treatments.

Gene and Cell Therapy

JERUSALEM, Jan. 12, 2022 (GLOBE NEWSWIRE) — Recently, a start-up project “LifeBank Chain (LBC)” in Israel is utilizing advanced gene and cell technologies over blockchain to develop advanced therapies. They endeavor to further human longevity and expand access to genetics and cell treatments through cutting-edge technologies.

Gene therapy involves altering the genes inside human body’s cells in an effort to treat or stop disease. Genes that don’t work properly can cause disease. Gene therapy is the introduction of genes into existing cells to prevent or cure a wide range of diseases. Gene therapy is an exciting new approach that is just making the news. And it will change the field of medicine from what it is today. As scientists discover more genes and their functions, the potential of LBC’s treatment is limitless.

Cell therapy is a therapy in which viable cells are injected, grafted or implanted into a patient in order to effectuate a medicinal effect, for example, by transplanting T-cells capable of fighting cancer cells via cell-mediated immunity in the course of immunotherapy. LBC’s cellular therapies are designed to improve the immune system’s ability to fight cancer. Manufacturing them involves collecting a specific set of cells from the blood, modifying them to produce a more vigorous attack on a patient’s cancer cells, and then reinjecting them into the patient.

Immune therapy is a new class of cancer treatment designed to boost or enhance the body’s immune system to more efficiently target and destroy cancerous cells. Many experts believe that immunotherapy represents the most promising new cancer treatment since the development of chemotherapy.

LifeBank Chain (LBC) is on this journey. As a full-solution ancillary reagent, services, and instrument provider, LBC will provide flexible and pioneering tools to simplify patient workflow at every step of the manufacturing process.

Count on LBC to provide solutions focused on:

  • Innovation
  • Scalability
  • Flexibility and Customization
  • Consistency and Reproducibility
  • Reducing Manufacturing Risk

To achieve this ultimate goal, LifeBank Chain establishes a professional, open, and shared social organization — LBC Life Alliance, inviting life technology companies, scientific research institutes, medical institutions, etc. to jointly solve medical, health, disease, and public health problems, and jointly build the application standards of gene and cell medical technology on the blockchain, and contribute to the cause of human health.

In order to promote the research of gene and cell therapy and the development of regenerative medicine, and ensure the safety and scientificity of gene and cell therapy and its research, LBC adopts comprehensive measures in relevant ethics, economy, law, technical management and public governance to create a better research environment for gene and cell therapy development.

LifeBank Chain:

https://lifebankchain.io

Twitter: https://twitter.com/lifebankchain

Email: lbc@lifebankchain.io

Related Images

Image 1: Gene and Cell Therapy

Gene and Cell Therapy Benefits to Everyone

This content was issued through the press release distribution service at Newswire.com.

Attachment

Jitterbit Acquires Low-Code Dev Innovator PrimeApps to Give Organizations a Radically New Way to Build Business Apps

End-to-End Platform Empowers Businesses to Create Secure and Scalable Digital Experiences, Slashing Costs and Development Time from Months to Days

ALAMEDA, Calif., Jan. 12, 2022 (GLOBE NEWSWIRE) — Jitterbit, the API transformation company, today announced it has acquired PrimeApps, a Turkey-based innovator in low-code application development. By combining Jitterbit’s API integrator with PrimeApps, the company will offer the first end-to-end platform that allows non-technical people to easily build and deploy business apps with enterprise-grade features that can connect to any system, all via a low-code, custom design interface.

“The pandemic has expedited businesses’ need to digitally transform. Talent shortages and disjointed technologies have made it nearly impossible for organizations to keep pace with change, innovate and stay ahead of the competition. Jitterbit’s acquisition of PrimeApps will give companies the springboard they need to gain a competitive edge in this new environment,” said George Gallegos, CEO of Jitterbit. “At the same time, this acquisition propels the company into the fast-growing low-code application platform (LCAP) market and expands Jitterbit’s domain expertise beyond iPaaS, providing customers and partners with a new set of capabilities.”

The integrated platform will enable businesses of any size to create secure and scalable digital experiences within days or even hours at a fraction of the cost, with no technical expertise required. The ability to connect applications easily across systems and workflows will enable hyperautomation, resulting in increased efficiency and consistency, fewer human errors, better intelligence and more.

“The promise of low-code development is now starting to come to life. By joining Jitterbit, we are becoming a first-mover that will help usher in this revolution, which will dramatically change how work gets done,” said Serdar Turan, CEO of PrimeApps. “With Jitterbit’s advanced iPaaS and APIM solutions, our platform will empower citizen developers, who are closest to their customers, to create new digital experiences that solve business challenges rapidly without having to rely on an army of IT engineers.”

Jitterbit will make the platform available in April 2022. Terms of the transaction were not disclosed. Additional details can be found here.

About Jitterbit, Inc.
Jitterbit, the API transformation company, makes it quicker and easier for businesses to exploit data from any source, empowering them to rapidly innovate and make faster, more effective decisions. The Jitterbit API integration and low-code application development platform enables companies to quickly create and connect SaaS, on-premise, and cloud applications and instantly infuse intelligence into any business process. To learn more, visit www.jitterbit.com and follow us on LinkedIn or @Jitterbit on Twitter.

Contact:
Jitterbit@bocacommunications.com

As Indonesia retakes land from developers, conservation is an afterthought

Published by
Mongabay

JAKARTA — Environmental activists have cautiously welcomed the Indonesian government’s move to revoke hundreds of permits for logging, plantations and mines, calling it an opportunity to conserve vast swaths of forest. The affected concessions include 192 earmarked for forestry and mines, totaling 3.13 million hectares (7.73 million acres), and 36 for plantations (at 34,448 hectares, or 85,123 acres). Together, they cover an area larger than Belgium. They were revoked because the concession holders had either abandoned them or failed to develop them. A preliminary analysis by environmental NGO… Continue reading “As Indonesia retakes land from developers, conservation is an afterthought”

Schneider Electric achieves outstanding performance in four corporate sustainability ratings

  • Strong and consistent performance running for over a decade
  • ESG recognition in line with company’s sustainable business growth ambitions

Rueil-Malmaison (France), January 12, 2022Schneider Electric, the leader in the digital transformation of energy management and automation, has delivered yet another strong year of Environmental, Social and Governance (ESG) performance based on 2021 ratings from independent and renowned corporate sustainability experts.

Schneider Electric uses the annual ratings from four key external indexes: CDP Climate Change, Dow Jones Sustainability World Index (DJSI), EcoVadis, and Vigeo Eiris, to grant shares to executives, senior management, leaders and talented employees determined as part of the Schneider Sustainability External & Relative Index (SSERI) long-term rewards scheme.

Motivating employees with sustainability targets based on external assessments is a necessity for any organization serious about driving and delivering positive impact, said Olivier Blum, Chief Strategy & Sustainability Officer, Rewarding people based on extra-financial performance is not only an encouragement, it’s a commitment to walk the talk.

Schneider Electric’s 2021 performance in the following ESG ratings underlines its long-standing sustainability leadership:

11th consecutive year on CDP’s Climate Change A list

  • Schneider Electric is among just 200 Climate Change A list companies out of 13,000+ companies assessed by CDP, and the only one in its sector to achieve this 11 years running
  • Schneider Electric is recognized for its commitment to measure and disclose the progress made on its carbon pledge

11th consecutive year on the Dow Jones Sustainability World Index

  • Schneider Electric listed among 322 companies, based on S&P Global’s Corporate Sustainability Assessment
  • Schneider Electric scored 86/100, compared to an industry average of 28/100

Top rating from EcoVadis

  • Schneider Electric remains in the top 1% of the 85,000 corporates assessed
  • Schneider Electric’s very high score (90/100) for sustainable procurement recognizes its ambitious supply chain decarbonization practices, including The Zero Carbon Project launched in 2021

#1 in its sector on the Vigeo Eiris index

  • Schneider Electric ranked first in the Electronic Components & Equipment sector in Europe
  • With a score of 71/100 ─ a five-point increase from the previous year, confirming inclusion in the Euronext Vigeo Eiris World 120, Europe 120, Eurozone 120 and France 20 indices

Achieving excellent ESG ratings across CDP, Vigeo Eiris, EcoVadis and DJSI in the same year is as difficult as staying at the top of these listings for over a decade,” commented Xavier Denoly, Senior Vice-President Sustainable Development. “I’m immensely proud of our teams and our work, but also very confident that we will deliver on our long-term sustainability targets.”

Schneider Electric has been accelerating its own sustainability efforts since the start of 2021 despite the pandemic. It has also reinforced its sustainability consulting business to support more partners and customers on their own sustainable transformation.

This dual sustainability strategy underpins the growth ambitions recently shared with investors during Schneider Electric’s Capital Markets Day 2021. Outstanding ESG performance substantiates the Group’s strong growth ambitions relating to sustainability.

About Schneider Electric

Schneider’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On.

Our mission is to be your digital partner for Sustainability and Efficiency.

We drive digital transformation by integrating world-leading process and energy technologies, end-point to cloud connecting products, controls, software and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure and industries.

We are the most local of global companies. We are advocates of open standards and partnership ecosystems that are passionate about our shared Meaningful Purpose, Inclusive and Empowered values.

www.se.com

Follow us on:

Discover the newest perspectives shaping sustainability, electricity 4.0, and next generation automation on Schneider Electric Insights

Hashtags: #LifeIsOn #Sustainability #ESG #OurImpact

Attachment

S.Korea authorises Novavax COVID-19 vaccine, imports Pfizer pills

Published by
Reuters

SEOUL (Reuters) -South Korea is turning to additional pharmaceutical tools as it looks to pre-empt a surge of COVID-19 omicron infections, authorising the use of Novavax Inc’s vaccine on Wednesday and preparing to distribute the first of Pfizer’s antiviral pills. At least 21,000 of Pfizer’s antiviral pills, called Paxlovid, will arrive in South Korea on Thursday, with another 10,000 more expected to arrive by the end of the month, the health ministry said. The pills, which were authorised for emergency use in December, will begin being used in treatments for more than 1,000 people per day star… Continue reading “S.Korea authorises Novavax COVID-19 vaccine, imports Pfizer pills”

Philips provides update on its financial performance in Q4 2021

January 12, 2022 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today provided an update on the fourth-quarter 2021 and full-year 2021 financial results.

Group sales for the quarter are expected to be approximately EUR 4.9 billion, which is around EUR 350 million lower than Philips’ earlier expectations. This is mainly due to intensified global supply chain shortages (primarily related to electronic components and freight capacity), as well as the postponement of customer equipment installations. The comparable sales [1] decline was approximately 10%, mainly due to these effects and the impact of the earlier announced Philips Respironics recall.* Group Adjusted EBITA [2] for the quarter is expected to be approximately EUR 650 million, which is approximately 13% of sales, impacted by the decline in sales and higher supply costs.

Consequently, Group sales for the full year 2021 are now expected to be approximately EUR 17.2 billion, resulting in an expected Group comparable sales decline of approximately 1% for the year. The supply chain headwinds combined with the impact related to the Philips Respironics recall* amounted to an impact of approximately 5 percentage points on the Group’s full year comparable sales. Group Adjusted EBITA for the full year is expected to be around EUR 2.1 billion, or approximately 12% of sales.

Group comparable order intake growth in the fourth quarter has remained robust with 4% growth driven by double-digit-growth in the Diagnosis & Treatment businesses, resulting in 4% growth for the full year 2021. This further builds on the high-single-digit comparable order intake growth in Q4 2020 and full-year 2020.

“We continue to see good demand for our innovative products and solutions, resulting in an all-time high order book,” said Frans van Houten, CEO of Royal Philips. “However, we faced significantly intensified global supply chain issues across our businesses, in addition to customer postponement of equipment installations in hospitals. We are closely working with suppliers and governments to address the shortages in the healthcare supply chain and ensure they recognize the importance of prioritizing life-saving medical equipment.”

Group restructuring, acquisition-related and other charges in the fourth quarter are expected to amount to EUR 420 million, which is EUR 315 million above the previously guided charges due to a further increase of the field action provision related to the voluntary Philips Respironics recall notification* (see below) and a provision for quality actions and other matters in the Connected Care businesses.

Update on voluntary Philips Respironics recall notification*
Philips Respironics is increasing the field action provision by around EUR 225 million, mainly due to the higher volume of devices now requiring remediation and increased supply costs. Philips Respironics expanded the scope to certain older devices in the interest of patients and in alignment with the relevant competent authorities and now expects to remediate a total of approximately 5.2 million registered devices globally.

“Patient well-being is at the heart of everything we do at Philips, and we aim to get a solution to patients as fast as possible,” said Frans van Houten. “To date, Philips Respironics has produced a total of approximately 1.5 million repair kits and replacement devices, of which approximately 700,000 have reached customers. I am also encouraged by the positive VOC test results to date for the first-generation DreamStation devices, which we published in December 2021 [3].”

Philips will discuss today’s announcement in a conference call from 09.00 to 09:30 am CET, January 12, 2022. The fourth-quarter and full-year 2021 financial results will be reported on January 24, 2022.

*       Recall notification in the US/field safety notice outside the US.

[1]    Comparable sales exclude the effect of currency movements and acquisitions and divestments (changes in consolidation). Philips believes that comparable sales information enhances understanding of sales performance.
[2]    Adjusted EBITA is defined as Income from operations (EBIT) excluding amortization of acquired intangible assets, impairment of goodwill and other intangible assets, restructuring charges, acquisition-related costs and other one-time charges and gains.
[3]   Philips Respironics continuous to make good progress with the comprehensive test and research program to better assess and scope potential patient health risks related to possible emission of particulates from degraded foam and certain volatile organic compounds (VOCs). In December 2021, Philips provided an update on the positive VOC test results to date for the first-generation DreamStation devices. The first-generation DreamStation devices represent the majority of the registered affected devices. Further testing is ongoing.

For further information, please contact:

Steve Klink
Philips Global Press Office
Tel.: +31 6 10888824
E-mail: steve.klink@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

US Charges Man With Giving Illegal Drugs to Athletes for Tokyo Olympics

U.S. prosecutors have charged a man with supplying performance-enhancing drugs to athletes at the Tokyo Olympics, a first under a federal law allowing criminal charges against doping conspirators at events involving U.S. athletes, broadcasters and sponsors.

The U.S. Attorney’s Office in Manhattan said Eric Lira, 41, distributed drugs, including human growth hormone, “for the purpose of corrupting” the Tokyo Games.

Lira obtained misbranded versions of prescription drugs used to boost production of red blood cells from Central and South America and distributed them to two athletes, prosecutors said.

One of the athletes believed to be discussed in the criminal complaint but not identified there by name is Nigerian sprinter Blessing Okagbare.

She was provisionally banned by an international anti-doping entity, the Athletics Integrity Unit (AIU), after testing positive for human growth hormone.

Lira was charged under the Rodchenkov Act, a law enacted at the end of 2020 and named for Russian whistleblower Grigory Rodchenkov. It lets prosecutors seek prison terms of up to 10 years and fines of up to $1 million for offenders.

The charges against Lira marked the first U.S. criminal accusations of doping related to the Tokyo Games, which were scheduled for 2020 but delayed to the summer of 2021 because of the COVID-19 pandemic.

“The Games offered thousands of athletes validation after years of training,” Damian Williams, the U.S. Attorney in Manhattan, said in a statement. “Eric Lira schemed to debase that moment by peddling illegal drugs.”

The World Anti-Doping Agency (WADA), which had voiced concerns about the Rodchenkov Act, said in an email to Reuters it, “Welcomes efforts by governments to penalize those who are trafficking or distributing prohibited substances.”

The head of the AIU, Brett Clothier, said, “Collaboration between law enforcement and anti-doping agencies can considerably strengthen the ability to detect serious doping, as is alleged in this case.”

Lira, a therapist based in El Paso, Texas, was arrested Wednesday.

Appearing via Zoom before U.S. Magistrate Judge Miguel Torres in El Paso, Lira, wearing a dark blue button-down T-shirt and surgical face mask, said he was “not very aware of the charges” and was in the process of hiring a private lawyer.

Torres scheduled a bail hearing for January 18 and turned Lira over to the custody of the U.S. Marshals Service.

‘Huge win’

Travis Tygart, chief executive of the U.S. Anti-Doping Agency, in a statement called the charges “a huge win for all clean athletes and those who value fair sport.”

Prosecutors said they had obtained encrypted messages in which Lira and one of the athletes discussed the athlete’s performance running the 100 meters, suggesting the athlete was a sprinter involved in the athletics competition.

“Eric my body feel so good (sic), I just ran 10.63 with a 2.7 wind, I’m so happy,” the athlete wrote to Lira on June 22, 2021, according to one of the messages obtained by prosecutors. “Whatever you did, is working so well.”

Some details in the complaint, including race dates and times and the athlete’s suspension, correspond with Okagbare, who had won a silver medal in the long jump at the Beijing Olympics in 2008.

Okagbare did not respond to a Reuters request for comment.

She had competed in the 100-meter heats at the Tokyo Olympics and was scheduled to run in the semifinal before being suspended.

The AIU said Okagbare had previously tested positive and charged her with the presence and use of a prohibited substance following the detection of human growth hormone.

Source: Voice of America